Vanguard Health Care Fund Investor Shares (VGHCX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vanguard Health Care Fund Investor Shares (VGHCX) trades at $211.09 with AI Score 44/100 (Grade C). Vanguard Health Care Fund Investor Shares (VGHCX) provides investors with exposure to the health care industry through investments in pharmaceutical, medical supply, and research companies. Market cap: $36.96B, Sector: Financial services.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for VGHCX: VGHCX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VGHCX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VGHCX: the 1 perspectives are evenly split.
How is this calculated? →Vanguard Health Care Fund Investor Shares (VGHCX) Financial Services Profile
Vanguard Health Care Fund Investor Shares (VGHCX) is an actively managed fund providing low-cost exposure to the healthcare sector, including pharmaceutical, medical supply, and research firms. With a focus on geographical diversification and lower turnover, VGHCX offers a complementary investment option for diversified portfolios seeking long-term growth within the healthcare industry.
What Is the Investment Thesis for VGHCX?
Vanguard Health Care Fund Investor Shares (VGHCX) presents a focused investment opportunity within the healthcare sector. The fund's key value driver is its low-cost structure, providing investors with efficient access to a diversified portfolio of healthcare companies. With a beta of 0.70, VGHCX exhibits lower volatility compared to the broader market, potentially offering a more stable investment option. Growth catalysts include the ongoing demand for healthcare services driven by aging populations and advancements in medical technology. The fund's emphasis on geographical diversification further enhances its growth potential by tapping into healthcare markets worldwide. However, investors should be aware of the fund's narrow focus on the healthcare sector, which exposes it to sector-specific risks and potential underperformance relative to broader market indices. The fund's long-term success hinges on its ability to navigate the evolving healthcare landscape and capitalize on emerging opportunities while maintaining its low-cost advantage.
Based on FMP financials and quantitative analysis
VGHCX Key Highlights
- Market Cap of $36.96B indicating substantial investment in the healthcare sector.
- Beta of 0.70 suggesting lower volatility compared to the broader market, offering a potentially more stable investment.
- Actively managed fund providing investors with expert selection of healthcare companies.
- Focus on geographical diversification mitigating risk by spreading investments across different regions and healthcare systems.
- Low turnover strategy reducing transaction costs and potentially leading to greater tax efficiency for investors.
Who Are VGHCX's Competitors?
VGHCX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MIEIX MFS Institutional International Equity Fund | $42.54 | +1.77% | $29.66B | 44 |
| PREIX T. Rowe Price Equity Index 500 Fund | $194.19 | +0.01% | $40.25B | 44 |
| PRWCX T. Rowe Price Capital Appreciation Fund | $38.08 | +0.11% | $39.23B | 44 |
| RBHEX American Funds 2050 Target Date Retirement Fund | $25.21 | -0.36% | $43.41B | 44 |
| RRMGX T. Rowe Price Mid-Cap Growth Fund | $88.04 | -0.33% | $29.75B | 44 |
| NXDT NexPoint Diversified Real Estate Trust | $5.53 | +3.08% | $285.77M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VGHCX's Key Strengths?
- Low-cost structure
- Geographical diversification
- Lower turnover rate
- Experienced management team
What Are VGHCX's Weaknesses?
- Narrow focus on the healthcare sector
- Potential for sector-specific risks
- Dependence on the performance of healthcare companies
- No dividend yield
What Could Drive VGHCX Stock Higher?
- Aging global population driving increased demand for healthcare services.
- Advancements in medical technology creating new investment opportunities.
- Potential regulatory changes in the healthcare industry impacting investment strategies.
- Increasing prevalence of chronic diseases fueling demand for healthcare products and services.
What Are the Key Risks for VGHCX?
- Regulatory changes in the healthcare industry impacting profitability.
- Economic downturn affecting healthcare spending and investment returns.
- Increased competition from other healthcare funds.
- Sector-specific risks associated with the healthcare industry.
- Patent expirations and generic competition impacting pharmaceutical company revenues.
What Are the Growth Opportunities for VGHCX?
- Expansion into Emerging Markets: VGHCX can capitalize on the rapidly growing healthcare markets in emerging economies. As these countries develop and their populations gain access to better healthcare, the demand for pharmaceuticals, medical devices, and healthcare services will increase significantly. By increasing its investments in companies operating in these regions, VGHCX can tap into a new source of growth and diversify its portfolio. The emerging market healthcare sector is projected to reach $1.7 trillion by 2030, presenting a substantial opportunity for VGHCX.
- Increased Investment in Biotechnology: The biotechnology industry is at the forefront of medical innovation, developing new treatments and therapies for a wide range of diseases. By increasing its allocation to biotechnology companies, VGHCX can benefit from the potential for high growth and returns. The global biotechnology market is expected to reach $3.88 trillion by 2034, growing at a CAGR of 12.3% from 2024. This presents a significant growth opportunity for VGHCX to capitalize on advancements in medical technology.
- Focus on Personalized Medicine: Personalized medicine, which tailors medical treatment to individual patients based on their genetic makeup and other factors, is a rapidly growing field with the potential to revolutionize healthcare. By investing in companies that are developing and commercializing personalized medicine technologies, VGHCX can position itself to benefit from this trend. The personalized medicine market is projected to reach $4.08 trillion by 2032, growing at a CAGR of 9.8% from 2023. This growth is driven by advancements in genetic sequencing and data analytics.
- Investment in Digital Health Technologies: Digital health technologies, such as telehealth, wearable devices, and mobile health apps, are transforming the way healthcare is delivered and accessed. By investing in companies that are developing and deploying these technologies, VGHCX can capitalize on the growing demand for convenient and affordable healthcare solutions. The global digital health market is expected to reach $660 billion by 2025, growing at a CAGR of 28.5% from 2020. This growth is fueled by increasing adoption of smartphones and internet access.
- Strategic Partnerships with Healthcare Providers: VGHCX can enhance its growth prospects by forming strategic partnerships with healthcare providers, such as hospitals and clinics. These partnerships can provide VGHCX with access to new investment opportunities and insights into the evolving needs of the healthcare market. By collaborating with healthcare providers, VGHCX can identify promising companies and technologies that are poised for growth. These partnerships can also help VGHCX to better understand the challenges and opportunities facing the healthcare industry.
What Opportunities Does VGHCX Have?
- Expansion into emerging markets
- Increased investment in biotechnology
- Focus on personalized medicine
- Investment in digital health technologies
What Threats Does VGHCX Face?
- Regulatory changes in the healthcare industry
- Increased competition from other healthcare funds
- Economic downturn affecting healthcare spending
- Patent expirations and generic competition
What Are VGHCX's Competitive Advantages?
- Low-cost structure attracting cost-conscious investors.
- Geographical diversification mitigating risk and enhancing growth potential.
- Lower turnover rate reducing transaction costs and improving tax efficiency.
- Established reputation of Vanguard as a trusted investment manager.
What Does VGHCX Do?
Vanguard Health Care Fund Investor Shares (VGHCX) has been providing investors access to the healthcare sector for over 25 years. The fund operates as an actively managed investment vehicle, focusing on companies involved in various facets of the healthcare industry. These include pharmaceutical firms developing and manufacturing drugs, medical supply companies producing equipment and devices, and research firms engaged in advancing medical knowledge and technologies. VGHCX distinguishes itself through its commitment to low-cost investing, making it an accessible option for a wide range of investors. The fund's investment strategy emphasizes geographical diversification, seeking opportunities in both domestic and foreign markets. This approach aims to mitigate risk by spreading investments across different regions and healthcare systems. Furthermore, VGHCX maintains a lower portfolio turnover rate compared to many other healthcare funds. This strategy reduces transaction costs and can lead to greater tax efficiency for investors. While VGHCX offers targeted exposure to the healthcare sector, its narrow focus means returns can fluctuate significantly from year to year. As such, it is best suited as a component of a well-diversified portfolio with a long-term investment horizon. The fund is managed by Vanguard, a well-established investment management firm known for its commitment to low-cost investing and investor-focused principles.
What Products and Services Does VGHCX Offer?
- Invests in a diversified portfolio of healthcare companies.
- Focuses on pharmaceutical firms, medical supply companies, and research firms.
- Offers low-cost exposure to the healthcare sector.
- Emphasizes geographical diversification in its investments.
- Maintains a lower portfolio turnover rate compared to other healthcare funds.
- Actively manages the fund to achieve its investment objectives.
- Provides investors with access to the growth potential of the healthcare industry.
How Does VGHCX Make Money?
- Generates revenue through management fees charged to investors.
- Invests in a portfolio of healthcare companies.
- Seeks to provide long-term capital appreciation for its investors.
What Industry Does VGHCX Operate In?
Vanguard Health Care Fund Investor Shares (VGHCX) operates within the asset management industry, specifically focusing on the healthcare sector. The healthcare industry is experiencing growth driven by factors such as aging populations, increasing prevalence of chronic diseases, and advancements in medical technology. The competitive landscape includes other healthcare-focused funds such as MIEIX, PREIX, PRWCX, RBHEX, and RRMGX, each with its own investment strategy and risk profile. VGHCX differentiates itself through its low-cost structure, geographical diversification, and lower turnover rate, appealing to investors seeking efficient and diversified exposure to the healthcare market.
Who Are VGHCX's Key Customers?
- Individual investors seeking exposure to the healthcare sector.
- Institutional investors looking for diversified healthcare investments.
- Retirement savers seeking long-term growth in the healthcare industry.
How Vanguard Health Care Fund Investor Shares Is Valued
Relative to its peer group, VGHCX's quantitative score of 44/100 is roughly in line with the peer average of 44/100.
VGHCX Financials
Bull Case vs Bear Case
Bull Case
- VGHCX benefits from the consistently high demand for healthcare services, making it a relatively stable investment during economic uncertainty.
- The fund's broad diversification across different healthcare sectors reduces the risk associated with individual company performance.
- Positive community sentiment suggests many investors believe in the long-term growth potential of the healthcare industry.
- Recent developments in healthcare technology and innovation could drive future growth for companies held within the fund.
Bear Case
- Regulatory changes in the healthcare industry can significantly impact the profitability of companies within the fund.
- Rising interest rates and inflation may lead to reduced consumer spending on non-essential healthcare services, affecting company revenues.
- Negative community sentiment regarding certain pharmaceutical companies within the fund could lead to investor uncertainty.
- Market perception of increased competition among healthcare providers might pressure the fund's overall performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VGHCX Latest News
No recent news available for VGHCX.
VGHCX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VGHCX.
Price Targets
Wall Street price target analysis for VGHCX.
VGHCX MoonshotScore
What does this score mean?
The MoonshotScore rates VGHCX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Common Questions About VGHCX (Financial Services)
What does Vanguard Health Care Fund Investor Shares do?
Vanguard Health Care Fund Investor Shares (VGHCX) is an actively managed mutual fund that invests primarily in the stocks of companies involved in the healthcare industry. This includes pharmaceutical firms, medical device manufacturers, biotechnology companies, and healthcare service providers. The fund aims to provide investors with long-term capital appreciation by focusing on companies that are expected to benefit from the growth of the healthcare sector. VGHCX offers a diversified approach to investing in healthcare, with a focus on both domestic and international companies and a commitment to low costs.
What are the main risks for VGHCX?
The main risks for VGHCX include sector-specific risks associated with the healthcare industry, such as regulatory changes, patent expirations, and product liability lawsuits. The fund's performance can also be affected by economic downturns, which can lead to reduced healthcare spending. Additionally, increased competition from other healthcare funds and changes in investor sentiment towards the healthcare sector can impact the fund's returns. Investors should carefully consider these risks before investing in VGHCX.
How is Vanguard Health Care Fund Investor Shares adapting to regulatory changes in the healthcare industry?
Vanguard Health Care Fund Investor Shares actively monitors regulatory developments within the healthcare industry to anticipate and adapt to potential impacts on its portfolio companies. The fund's management team analyzes proposed and enacted legislation, assessing the implications for pharmaceutical pricing, healthcare delivery models, and medical device approvals. By understanding these regulatory shifts, VGHCX can adjust its investment strategy to favor companies that are well-positioned to navigate the changing landscape and mitigate potential risks, ensuring long-term value for its investors. This proactive approach is crucial in the highly regulated healthcare sector.
What are the key performance indicators (KPIs) that Vanguard uses to measure the success of VGHCX?
Vanguard employs several key performance indicators (KPIs) to assess the success and effectiveness of VGHCX. These include the fund's total return compared to its benchmark index, the expense ratio relative to its peers, and the fund's tracking error, which measures how closely it follows its benchmark. Additionally, Vanguard monitors the fund's risk-adjusted return, such as the Sharpe ratio, to evaluate the return generated per unit of risk taken. Portfolio turnover rate is also a key metric, reflecting the fund's trading activity and associated costs. These KPIs provide a comprehensive view of VGHCX's performance and efficiency.
What are the key factors to evaluate for VGHCX?
Vanguard Health Care Fund Investor Shares (VGHCX) holds an AI score of 44/100 (low). Not financial advice.
How frequently does VGHCX data refresh on this page?
VGHCX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VGHCX's recent stock price performance?
Vanguard Health Care Fund Investor Shares (VGHCX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Low-cost structure. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VGHCX overvalued or undervalued right now?
Valuing Vanguard Health Care Fund Investor Shares (VGHCX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and should not be considered investment advice.
- Investors should conduct their own research and consult with a financial advisor before making any investment decisions.